Atlas Trials

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Clinical trial NCT03896503 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03896503
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Extensive Stage Lung Small Cell CarcinomaExtrapulmonary Small Cell Neuroendocrine CarcinomaLimited Stage Lung Small Cell CarcinomaPlatinum-Resistant Lung Small Cell CarcinomaPlatinum-Sensitive Lung Small Cell CarcinomaRecurrent Lung Small Cell Carcinoma
Start date
2019-12-30
Primary completion
2022-12-19
Enrollment
104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.